Summary. Assessing per-protocol treatment efficacy on a time-to-event endpoint is a common objective of randomized clinical trials. The typical analysis uses the same method employed for the intention-to-treat analysis (e.g., standard survival analysis) applied to the subgroup meeting protocol adherence criteria. However, due to potential post-randomization selection bias, this analysis may mislead about treatment efficacy. Moreover, while there is extensive literature on methods for assessing causal treatment effects in compliers, these methods do not apply to a common class of trials where a) the primary objective compares survival curves, b) it is inconceivable to assign participants to be adherent and event-free before adherence is measured, and c) the exclusion restriction assumption fails to hold. HIV vaccine efficacy trials including the recent RV144 trial exemplify this class, because many primary endpoints (e.g., HIV infections) occur before adherence is measured, and nonadherent subjects who receive some of the planned immunizations may be partially protected. Therefore, we develop methods for assessing per-protocol treatment efficacy for this problem class, considering three causal estimands of interest. Because these estimands are not identifiable from the observable data, we develop nonparametric bounds and semiparametric sensitivity analysis methods that yield estimated ignorance and uncertainty intervals. The methods are applied to RV144.
Introduction
Over the past 30 years, millions of individuals have acquired HIV and the global rate of new infections remains high. Unfortunately, the development of an HIV vaccine has been difficult with clinical trials not yielding promising results. However, a recent community-based, individually-randomized, multicenter, double-blind, placebocontrolled clinical trial of 16,395 HIV negative volunteers in Thailand (the RV144 'Thai trial') supported that an HIV vaccine regimen had partial efficacy to reduce the risk of HIV infection (Rerks-Ngarm et al. 2009 ). This trial administered four injections of a recombinant canarypox vector vaccine (or placebo) at the Week 0, 4, 12, 24 study visits, plus two injections of a recombinant glycoprotein 120 subunit vaccine (or placebo) at the Week 12, 24 study visits, and monitored participants for the primary endpoint of HIV infection from entry until the final study visit at 3.5 years. While the Thai trial's finding of partial efficacy generated great enthusiasm as the first positive finding from an HIV vaccine efficacy trial, it also generated confusion, because the results on vaccine efficacy appeared to differ depending on whether the analysis utilized the modified intention-to-treat (MITT) or per-protocol (PP) cohort, where the MITT cohort was all randomized subjects HIV negative at baseline (determined via blinded procedures), and the PP cohort was the subset of the MITT cohort that tested HIV negative at the Week 24 study visit and received all 6 study injections at the Week 0, 4, 12, 24 study visits within pre-specified allowable visit windows. With vaccine efficacy (V E) defined as the percent reduction in the cumulative probability of HIV infection diagnosis by 39 months post-randomization (vaccine versus placebo), estimated based on KaplanMeier estimates, the MITT result was V E = 31%, 95% CI 0% to 51%, p = 0.04 and the PP result was V E = 25%, 95% CI -16% to 51%, p = 0.19. While the point estimates were fairly close to one another and hence there was little evidence for different effects, nonetheless many observers expressed concern that V E was apparently lower in the PP cohort.
Due to randomization, the comparator groups in the MITT analysis are guaranteed to have balanced baseline prognostic factors on average, such that the MITT analysis provides consistent estimation of a causally-interpretable V E parameter, namely the percent reduction in the cumulative risk of infection if everyone were assigned vaccine compared to if everyone were assigned placebo. On the other hand, the comparator groups in the PP analysis are subsets of randomized subjects whose membership is determined conditional on post-randomization variables, resulting in possible selection bias (Rosenbaum, 1984) , such that the PP analysis does not necessarily assess a causal effect of vaccination. Rather, it assesses a mixture of the effect of vaccine assignment and imbalanced prognostic factors created by conditioning on qualification into the PP cohort. The PP analysis included 24% fewer subjects and 31% fewer primary endpoint events than the MITT analysis. Table 1 summarizes the reasons why MITT subjects failed to qualify for the PP cohort. The rate of nonadherence to study injections was significantly higher in the vaccine than placebo group (24% versus 21%, Chi-squared test p < 0.001), possibly due to a higher rate of reactogenicity in the vaccine group (79% versus 59%) (Rerks-Ngarm et al. 2009 ).
As discussed in Gilbert et al. (2011) , opinions varied on the interpretation of the results, ranging from discounting the PP analysis because only the MITT analysis provides an asymptotically unbiased answer to a question of clear interest (typically statisticians), to discounting any inference about positive vaccine efficacy because one would expect the vaccine to work better in those who received all of the immunizations Table 1 : Culling of the MITT Cohort to Form the PP Cohort in the RV144 Thai Trial problematic interpretation of the PP analysis renders it of marginal value, whereas the latter interpreters are correct that, were V E in vaccine-adherent subjects to be assessed in a more meaningful way, it would indeed add value.
To improve upon the standard analysis of V E in the PP cohort, an analytic method that adjusts for subject factors known to predict PP cohort membership and HIV infection (such factors may cause selection bias) should be applied (e.g., see Tsiatis et al. 2008) , which in addition to correcting for bias can improve statistical power by leveraging prognostic factors. Moreover, because some biasing factors may be unmeasured, the sensitivity of results to such factors should also be investigated. However, existing approaches to sensitivity analysis do not directly apply to vaccine efficacy trials, or, more generally, to two-arm randomized trials of treatments where the primary objective compares survival curves, some participants experience the primary endpoint before adherence is evaluated, and some subjects have partial adherence (implying that the exclusion restriction assumption is implausible; see Section 3 for the definition and interpretation of this assumption in our context). Therefore in this article we develop methods for this class of trials. The methods apply to most vaccine efficacy trials, given that almost all such trials assess per-protocol V E (Horne, Lachenbruch, and Goldenthal, 2001) , and typically multiple immunizations are administered over a period of months during which disease events occur. Moreover, over the past several decades the standard non-causal per-protocol analysis has been ubiquitously applied to such efficacy trials, and this work aims to help improve the standard approach by adding causal assessment.
This manuscript is organized as follows. In Section 2 we define notation and three PP treatment effect estimands, and place the current work in the context of previously developed methodology for evaluating causal effects in compliers. In Section 3 assumptions are given that help identify the estimands under four different assumption sets. In Sections 4 and 5 we describe non-and semi-parametric methods for inference including techniques for estimating ignorance and uncertainty intervals. The methods are developed under multiple assumption sets so that practitioners may tailor the sensitivity analysis approach to their particular trial; where stronger assumptions are warranted the estimated ignorance and uncertainty intervals will tend to be narrower.
In Section 6 we apply the methods to the Thai trial. The methods are implemented using the sensitivityPStrat package in R available on CRAN and our complete analysis code is posted at the second author's website.
Notation, Per-Protocol Estimands, and Problem Context
Consider a two-group randomized trial, wherein subjects are randomly assigned to treatment Z = 1 or Z = 0 (in our motivating example Z = 1 is vaccine and Z = 0 is placebo) and are followed for the primary time-to-event endpoint (typically a disease event). Let T be the time from randomization until the disease event and C be the censoring time, such that X = min(T, C) and ∆ = I(T ≤ C) are observed. Let A be an indicator of adherence/compliance to assigned treatment defined based on study visits between randomization through time τ 0 . For example, in the Thai trial, study injections were scheduled at Week 0, 4, 12, 24 visits, and A = 1 was defined as receipt of all planned injections within the pre-specified allowable visit windows. Note that A = 1 for Z = 1 subjects indicates appropriate receipt of vaccination injections whereas A = 1 for Z = 0 subjects indicates appropriate receipt of placebo injections. We treat A as undefined if T ≤ τ 0 , denoted by A = * , and assume the data are iid observations
The population of interest for inference is disease-free and adherent up to τ 0 . Thus, the PP cohort of interest is {i : T i > τ 0 , A i = 1}, and we define P P = I(T > τ 0 , A = 1).
Let S P P obs z (t) ≡ P (T > t|Z = z, T > τ 0 , A = 1) be the survival function in the PP cohort if assigned treatment Z = z for t ≥ τ 0 , and F P P obs z
. It is widespread in clinical trials to measure per-protocol treatment efficacy by a contrast in S P P obs 1 (t) and S P P obs 0 (t), which does not measure a causal effect. Below we define three survival causal effect (SCE) estimands that account for adherence/compliance.
The first estimand of interest is based on the literature for assessing causal treatment effects in "always compliers," "always infected," or "always survivors" (Angrist, Imbens, and Rubin, 1996; Frangakis and Rubin, 2002; Shepherd, Gilbert, and Lumley, 2007; Shepherd, Gilbert, and Dupont, 2011, henceforth SGD) . Let T (z), C(z), X(z), ∆(z), A(z) be the potential outcomes of T, C, X, ∆, A under assignment Z = z for z = 0, 1. Let S z (t) ≡ P (T (z) > t), F z (t) ≡ 1 − S z (t), and P P (z) ≡ I(T (z) > τ 0 , A(z) = 1), and set pp z ≡ P (P P (z) = 1). For x, y ∈ [0, 1] let h(x, y) be a known contrast function satisfying h(x, x) = 0 and h(x 1 , y 1 ) ≤ h(x 2 , y 2 ) for all x 1 ≤ x 2 and y 1 ≥ y 2 , such as
With the always-compliers approach, the survival causal effect estimand is
where S AP P z (t) ≡ P (T (z) > t|P P (1) = P P (0) = 1) for z = 0, 1. The estimand SCE AP P (t) measures the causal treatment effect in "always per-protocol" (AP P ) subjects, {P P (1) = P P (0) = 1}, i.e., subjects who would survive to τ 0 under both treatments and would be compliant to whatever they were assigned. One appeal of this estimand is that always compliers may be persuaded to follow a treatment policy.
The second survival causal effect estimand of interest is
where
evaluates "always survivors" (AS) to time τ 0 who would be adherent under Z = 1.
This estimand differs from SCE AP P (t) by measuring treatment efficacy in those adherent to treatment 1, regardless of whether they would adhere to treatment 0. This subpopulation is of interest because, once a treatment is licensed, treatment decisions and policies will largely be based on the predicted effect of that treatment for those who take it, whereas adherence to a control preparation may no longer be relevant.
Follmann (2000) and Loeys and colleagues cited below studied the same subpopulation of "would-be treatment compliers." We view the AP P and ASA1 estimands as complementary, each of interest in its own right and capturing different information.
While there is a rich literature for assessing causal treatment effects in always compliers or would-be treatment compliers, most papers have not accommodated an outcome subject to censoring, and, among those that do, an assumption is made that renders the method inapplicable in our context. Cuzick et al. (2007) developed a structural proportional hazards model (SPHM) for estimating a hazard ratio estimand in the AP P subpopulation; however, they assume adherence status A is known at randomization. Closer to our setting in assuming A is measured after randomization, Loeys and Goetghebeur (2003) and Loeys, Goetghebeur, and Vandebosch (2005) developed an SPHM for estimating a hazard ratio estimand in the ASA1 subpopulation assuming all-or-none or time-constant adherence and A(0) = 1 for all subjects, in which case the method equivalently applies to the AP P subpopulation. This work does not apply to our setting because it assumes the exclusion restriction, and because we are specifically interested in comparing survival curves, which allows assessing treatment efficacy over time and avoids the built-in selection bias of hazard ratios (Hernán, 2010) . Baker (1998) and Nie, Cheng, and Small (2011) developed nonparametric likelihood estimation-based approaches for the AP P estimand, but, in requiring the exclusion restriction, they also do not apply. SGD provided an applicable approach for the AP P estimand (1) that does assume the exclusion restriction, and a novel contribution of this article is to extend SGD to new identifiability assumption sets that are sometimes reasonable in double-blinded randomized trials.
The third survival causal effect estimand we study is
where are not perfectly correlated, it is easy to find examples where there is no marginal causal treatment effect on T , but there is an expected beneficial treatment effect S where ⊥ denotes independence. SUTVA states that potential outcomes for each subject i are unrelated to the assignment Z j of other subjects and that there are not multiple versions of treatment. We also consider additional assumptions involving the initial study period through τ 0 , which will be utilized to help identify the estimands.
Survival Monotonicity (SM): there should not be less adherence in the control group due to a preference to receive treatment. The stronger assumption EA states that all subjects retained and adherent under one assignment would also be so under the other. While this is implausible for trials of treatments with serious side effects, it may be plausible for double-blinded trials of non-toxic interventions in healthy populations (e.g., prevention trials).
We consider four types of assumption sets under which sensitivity analysis techniques are developed: (A) base set; (B) base set plus AM; (C) base set plus (SM, AM); (D) base set plus (SM, EA). These sets posit increasingly stringent assumptions.
SM, AM, and EA can be rejected based on data (e.g., SM is rejected if a test indicates
in any baseline subgroup), but they cannot be fully verified, given that they must hold for every individual. Supplementary Table 1 describes the basic principal strata (Frangakis and Rubin, 2002) formed based on T (1),
as well as the subpopulations defining the estimands under the assumption sets.
Given the relatedness of our problem with causal inference for compliers, it is noteworthy that we do not consider the exclusion restriction assumption that is commonly made. In our context this assumption is expressed as
e., the treatment has no effect in individuals non-adherent under each treatment assignment. This assumption may be plausible in settings with all-or-none adherence, for which A(1) = 0 indicates no receipt of treatment whatsoever.
However, in vaccine trials, several immunizations are planned and many subjects with A(1) = 0 receive some or even all immunizations (as for the Thai trial, see Table 1) , and hence could have a beneficial vaccine effect on infection (i.e., T (1) > T (0)). Also, unlike SM, AM, EA, the exclusion restriction would require making an assumption about the time period after τ 0 .
Semiparametric Sensitivity Analysis and Nonparametric Bounds
We develop semiparametric modeling approaches to sensitivity analysis for each estimand under each assumption set, which use a fixed sensitivity parameter(s) γ (not identifiable from the observed data and the base set of assumptions) within a specified
, and SCE # (t; γ) are indexed by γ ∈ Γ, where # denotes AP P , ASA1, or P P 1. We also develop nonparametric bounds, obtained by setting the sensitivity parameter(s) to extreme values. Our approach follows Robins (1997) and Vansteelandt et al. (2006) , where each estimand is nonparametrically identified once the sensitivity parameter(s) γ indexing the full data law M(γ) defined by modeling restrictions is fixed, and the goal is inference on the estimand under the union
, assuming the true value γ 0 of γ lies in Γ.
Estimands S

AP P 1
(t) and S
AP P 0 (t).
Assumption set A. As noted above, we will adapt the general sensitivity analysis method of SGD for making inferences about the AP P estimand. The base set of assumptions plus the following three selection models (and the observed data) identify
(t) and S AP P 0 (t):
is a fixed and known parameter, G 0 (·) is a known cdf, α 0 is an unknown parameter, and for each β 0 , h 0 (t; β 0 ) is a known function of t.
B.2: P (P P (0) = 1|P P (1) = 1, T (1) = t) = w 1 (t; α 1 , β 1 ) for t > τ 0 , where w 1 (t; α 1 , β 1 ) = G 1 {α 1 + h 1 (t; β 1 )}, β 1 is a fixed and known parameter, G 1 (·) is a known cdf, α 1 is an unknown parameter, and for each β 1 , h 1 (t; β 1 ) is a known function of t.
B.3: π AP P ≡ P (P P (1) = P P (0) = 1) is fixed and known.
B.1 models the dependency of P P (1) on the failure time T (0) in the {P P = 1, Z = 0} subgroup, and B.2 posits a similar model with the treatment assignments swapped.
The parameters γ = (β 0 , β 1 , π AP P ) are not identified by the observed data; they are sensitivity parameters, treated as known in a single analysis and varied over a range of values to form a sensitivity analysis (Scharfstein, Rotnitzky, and Robins, 1999) .
Following SGD, we specify each w z (t; α z , β z ) for z = 0, 1 with a modified inverse logit function,
where τ > τ 0 is some number less than or equal to the maximum length of follow-up.
The minimum of t and τ is used instead of t to avoid parametric assumptions about Models B.1 and B.2 may be equivalently expressed as pattern mixture models, which give the sensitivity parameters alternative interpretations that may be preferred by some practioners. For example, with weight (4), B.1 can be re-expressed as exp {β 0 t} = Pr(T (0) = t|P P (1) = 1, P P (0) = 1) Pr(T (0) = t|P P (1) = 0, P P (0) = 1) π AP P Pr(P P (1) = 0, P P (0) = 1) for t ∈ (τ 0 , τ ], such that exp{β 0 } is the density ratio (comparing the AP P and {P P (1) = 0, P P (0) = 1} subpopulations) of infection at time t divided by this density ratio at time t − 1. Thus β 0 calibrates the discrepancy between the distributions of T (0) for the AP P and {P P (1) = 0, P P (0) = 1} subpopulations.
B.3 specifies the probability a subject is always per-protocol. Instead of specifying π AP P , alternatively one could specify φ AP P ≡ π AP P /pp 1 = P (P P (0) = 1|P P (1) = 1).
Under B.1 and B.2, for z = 0, 1
Furthermore, algebra shows that
and therefore
Once β 0 , β 1 , π AP P are specified, α 0 and α 1 are identified based on (6), such that S AP P 0 (t) and S AP P 1 (t) are identified.
Under the base set of assumptions alone, nonparametric bounds for S AP P z (t) are achieved by setting π AP P to its smallest possible value and β z to −∞ and ∞, i.e., 
for t ≥ τ 0 and z = 0, 1. These bounds determine the nonparametric bounds for SCE AP P (t) for any contrast function h(·, ·) satisfying the properties described in Section 2, equal to
These bounds are nonparametric because no parametric modeling assumptions are used in expressing the bounds or in the procedures for estimating them (e.g., B.1-B.3 are not needed). The Supplementary Materials (Section 2) contain a proof of (8).
Assumption set B (add AM).
The same approach is used when AM is added, with the only difference being that the amount of possible post-randomization selection bias is reduced. In particular, π AP P is now constrained between max{0, S 0 (τ 0 ) + pp 1 − 1} and min{pp 0 , pp 1 }. In addition, in B.2 the weight function w 1 (t;
and by AM the first conditional probability is known to be one.
The nonparametric bounds for the AP P estimand under assumption set B are as
in (8) and (9) with π min modified to π min = max{0, S 0 (τ 0 ) + pp 1 − 1}, and are always at least as narrow as those under assumption set A. If there is nonadherence under treatment z = 0 such that pp 0 < S 0 (τ 0 ), then π AP P has a narrower range via the extra assumption AM, yielding narrower bounds (if π min > 0). This occurs in the Thai trial example.
Assumption set C (add SM, AM).
Again the same approach is used as under assumption sets A and B, with the amount of possible post-randomization bias further reduced by the constraint max{0,
Under SM, P P (1) = A(1), which simplifies the interpretation of β 0 to reflect the association of infection risk of per-protocol placebo recipients with adherence if vaccinated. The nonparametric bounds are the same as above with π min replaced with
, which by SM equals one. Therefore S AP P 0 (t) = S P P obs 0 (t). In addition, by EA model B.2 is expressed as w 1 (t;
, which we again model with the modified inverse logit function (4). SM and EA together identify π AP P as π AP P = pp 0 . Therefore only B.2 among the models (B.1, B.2, B.3) is needed, and simple calculations show that
where α 1 is the solution of (6) with z = 1 and π AP P = pp 0 . The nonparametric bounds for S AP P 1 (t) (for t ≥ τ 0 ) are given by (8) with π min = pp 0 and z = 1.
Nonparametric bounds under alternative assumption sets. Zhang and Rubin (2003) and Chiba (2012) derived nonparametric bounds for the average causal effect in "always survivors" under different assumptions than SM, AM, and EA. While we chose our assumption sets to be maximally relevant for vaccine trials, these alternative assumptions may also be plausible for some vaccine trials, and yield alternative nonparametric bounds for SCE AP P (t). Seven alternative assumption sets, their interpretations and plausibility for RV144, and the corresponding nonparametric bounds are described in Supplementary Materials (Section 3 and Supplementary Table 2 ).
Estimands S
ASA1 1 (t) and S ASA1 0
(t).
Assumption set A. The ASA1 estimands are identified using the same models as above, except the event {P P (0) = 1} is replaced with {T (0) > τ 0 }: 
Nonparametric bounds for SCE ASA1 (t) are constructed similarly as for SCE AP P (t), replacing F P P obs 0 (t) with F 
Assumption sets B, C, D.
Under AM included in B, C, and D, S AP P z
such that the identical methods described above for the AP P estimand apply.
Estimands S
P P 1 1 (t) and S P P 1 0 (t).
The base set of assumptions identify S P P 1 1 (t) (by S P P obs 1 (t)), but not S P P 1 0
(t).
Assumption set A. We write
and use a selection bias model parallel to B.1 and B.1':
, where again we specify w 0 (·) as modified inverse-logit as in (4). Straightforward calculation using (11) and B.1" shows that
where α ′′ 0 is the solution to
(t) is identifed from the base set of assumptions, nonparametric bounds for SCE P P 1 (t) derive from nonparametric bounds for S P P 1 0 (t). By similar derivations used in the proof of (8) in the Supplementary Materials, the bounds equal
The width of the bounds increases with the risk of early failure or nonadherence. In many applications, S 0 (t)/pp 1 > 1 for most or all t, such that the upper bound is one. B.2": P (P P (1) = 1|H(0) = 1, T (0) = t) = w 0 (t; α ′′ 0 , β ′′ 0 ) for t ≥ 0, such that
Assumption set B (add AM). Under AM, S
Simple calculations show that P (H(0) = 1) = 1 − S 0 (τ 0 ) + pp 0 and F
With w 0 (·) again the inverselogit function, β ′′ 0 is the log odds of P P (1) = 1 given H(0) = 1 and T (0) = t versus t − 1. In many applications {H(0) = 1} ≈ {P P (0) = 1} due to a much larger number of subjects in {P P (0) = 1} than in {T (0) ≤ τ 0 }, in which case β The nonparametric bounds are S P P 1 0,lo (t) ≤ S P P 1 0 (t) ≤ S P P 1 0,hi (t), where
The bounds (15) are at least as sharp as those computed under the base set, (13).
Assumption set C.
When SM is added, the methods are identical to those under assumption set B. Under assumption sets B and C, S P P 1 0
if π AP P = pp 1 , which occurs if P P (1) = 1 implies P P (0) = 1. Moreover, S P P 1 1
(t) if π AP P = pp 1 or P P (0) ⊥ T (1)|P P (1) = 1 (i.e., β 1 = 0 in B.2).
Assumption set D (add SM, EA). Under AM, S
P P 1 0 (t) = S AP P 0 (t)π AP P /pp 1 . SM and EA imply π AP P = pp 0 and S AP P 0 (t) = S P P obs 0 (t), such that S P P 1 0 (t) is identified by
and there are no sensitivity parameters. Therefore under SM and EA, the non-causal estimand SCE P P obs (t) ≡ h(S P P obs 1 (t), S P P obs 0 (t)) is corrected to a causal one through the adjustment constant pp 0 /pp 1 , which is ≤ 1. The formula shows how the correction depends on differential rates of early failure and adherence. Under assumption set D,
(t) = S P P 1 0 (t) = S P P obs 0 (t) if and only if pp 0 = pp 1 , which is testable. Table 2 lists the four assumption sets for each of the three estimands. 
same as in B. for AP P same as in B. for AP P
same as in C. for AP P same as in C. for AP P
N/A * B > 1 is a specified constant;t is a specified interpretable time-increment such as 1 year or the fixed follow-up period.
Maximum Likelihood Estimation and Uncertainty Intervals
We consider inference about the estimands SCE # (t). Estimators of SCE # (t; γ)
for a fixed value of the sensitivity parameter(s) γ are described in Section 5.1. Because γ is not identifiable, we recommend reporting an estimated ignorance interval, i.e., a set of point estimates SCE # (t; γ) with γ varied over a selected region Γ. Ignorance intervals express ambiguity about the parameter of interest due to partial identifiability; in contrast, traditional confidence intervals (given a particular fixed γ) express ignorance/ambiguity due to sampling variability only. Associated with ignorance regions, in Section 5.2 we describe procedures for constructing uncertainty intervals that incorporate imprecision due to sampling variability as well as to lack of identifiability.
Estimation of SCE
AP P (t), SCE ASA1 (t), and SCE P P 1 (t).
Given fixed γ, for each estimand and assumption set, maximum likelihood estimators (MLEs) of SCE # (t; γ) are constructed by plugging in MLEs for the quantities given in Section 4. Kaplan-Meier estimates (nonparametric MLEs) can be used to estimate F P P obs z (t), F τ 0 obs z (t), and F z (t), for z = 0, 1. MLEs for pp z are the proportion of subjects assigned treatment z with P P (z) = 1. Estimation proceeds by fixing sensitivity parameters and then solving for unknown parameters. For example, for the AP P estimand under assumption set A, using (6) and fixing β z and π AP P , the MLE of α z is the solution to
is obtained by plugging the MLEs into (7). The MLEs of the nonparametric bounds are obtained by substituting MLEs into (8) and (9). Estimation of the other estimands and under different assumption sets proceeds in a similar fashion.
As shown in Table 2 , the sensitivity parameters π # are constrained by functions of the identifiable parameters pp 1 , pp 0 , and S 0 (τ 0 ). Therefore the data may contradict certain choices of π # , precluding estimation via plug-in MLEs in the above equations. Accordingly, we suggest using the MLEs of pp 1 , pp 0 , and S 0 (τ 0 ) in the inequality bounds, as listed in Supplementary Table 3 . This approach is equivalent to re-parametrizing with an unconstrained sensitivity parameter (Supplementary Material, Section 3).
The data may violate an assumption that is nonetheless assumed. For example, assumption set D implies pp 0 ≤ pp 1 , but in the Thai trial pp 0 > pp 1 . In such cases the estimation procedure uses constrained MLEs; in this example, for the P P 1 estimand, pp 0 / pp 1 is forced to unity such that S P P 1 0 (t) = S P P obs 0 (t) by equation (16).
Estimated Ignorance Intervals and Uncertainty Intervals.
With Γ a specified region of sensitivity parameter values γ and γ 0 ∈ Γ the true value, we consider inference and uncertainty interval estimation for SCE # (t; γ 0 ) for fixed t ≥ τ 0 . For each fixed γ ∈ Γ, the bootstrap can be used to estimate the variances of S # z (t; γ) and SCE # (t; γ), as well as to construct percentile confidence intervals for S # z (t; γ) and SCE # (t; γ). To compute estimated ignorance and uncertainty intervals, we use the fact that for each estimand and assumption set, SCE # (t; γ) is monotone in γ. With one sensitivity parameter such as γ = β 1 , monotonicity implies that the extreme estimates SCE # (t; γ) are obtained by setting β 1 to its extreme values. With three sensitivity parameters such as γ = (β 0 , β 1 , π AP P ), monotonicity implies that the extreme estimates SCE # (t; γ) are obtained by setting each of the three parameters to an extreme value;
for example, Section 4.1 described how to achieve this for the AP P estimand. For a given analysis [estimand, assumption set, contrast function h(·, ·)], suppose the values γ l and γ u in Γ yield the minimum and maximum estimates SCE # (t; γ). The estimated ignorance interval is computed as SCE # (t; γ l ), SCE # (t; γ u ) . Supplementary Table   3 lists the data-dependent values of γ l and γ u to use in a standard plausible-range sensitivity analysis that we propose in Section 5.3.
Following Vansteelandt et al. (2006, Section 4 .1), a (1 − α) × 100% pointwise uncertainty interval is defined by random limits L # (t) and U # (t) satisfying
where P M(γ) indicates that probabilities are taken under M(γ). Such intervals are of interest because they contain the true SCE # (t; γ 0 ) with probability at least 1 − α. (2004) 1-sided confidence intervals for SCE # (t; γ) computed at γ = γ l and at γ = γ u , respectively. Here the significance level α does not need to be divided by two provided (Imbens and Manski, 2004) , which occurs for all of the proposed sensitivity analysis methods because γ l = γ u and SCE # (t; γ) is strictly monotone in γ. Based on similar derivations used in Shepherd, Gilbert, and Lumley (2007) , asymptotic normality of ( SCE # (t; γ l ), SCE # (t; γ u )) T holds under simple conditions (provided in Supplementary if the (1 − α) × 100% EUI excludes SCE * . The corresponding 2-sided p-value equals the smallest α such that the (1 − α) × 100% EUI excludes SCE * . This testing procedure has size bounded above by α, and thus has the desirable 1:1 correspondence with the EUIs. Alternatively, H inf 0 can be tested directly using the infimum test of Todem et al. (2010) , and their test inverted to obtain an (1 − α) × 100% EUI for SCE # (t, γ 0 ), namely the set of SCE * where H inf 0 is not rejected at significance level α.
Imbens and Manski
SCE # (t; γ u ) > SCE # (t; γ l )
A Suggested Standard Sensitivity Analysis.
Given that it is often challenging to obtain consensus among experts about the plausible range of sensitivity parameters, it may be useful to develop standards that, while somewhat arbitrary, can be uniformly applied and make causal per-protocol analyses more objective and interpretable. We suggest one possible standard, where the odds ratios exp(β 0 ) and exp(β 1 ) are varied between 1/B and B per incrementt in failure time T (0) and T (1), where the scalart and the bound B are selected by subject matter experts based on the context of the study (following the approach of Shepherd, Gilbert, and Mehrotra, 2007) . For example,t may simply be a 1-year interval. The plausible upper bounds for π AP P and π ASA1 are set at min{ pp 0 , pp 1 } and min{ S 0 (τ 0 ), pp 1 }, respectively, the MLEs of the maximum possible value. For assumption set A we suggest using the more plausible lower bound for π AP P of pp 1 pp 0 , corresponding to the MLE of π AP P if P P (0) and P P (1) were independent (negative correlation seems highly implausible). Similarly, we suggest using pp 1 S 0 (τ 0 ) as the plausible lower bound for π ASA1 .
Under assumption sets B and C we suggest setting π AP P and π ASA1 at the MLEs of the minimum possible values, which vary by assumption set, since AM and SM greatly constrain the ranges for π AP P and π ASA1 (values listed in Supplementary Table 3) . We also suggest reporting the nonparametric bounds as worst-case scenarios.
Example
We apply the above methodology to evaluate per-protocol vaccine efficacy in the Thai trial, using the vaccine efficacy contrast function h(x, y) = 1 − (1 − x)/(1 − y). The protocol definition of adherence required receiving all six immunizations at the four scheduled immunization visits within allowable visit windows by τ 0 ≡ 6.21 months after randomization. The trial followed subjects for HIV infection up to the terminal study visit at 42 months, and we focus on a time-point near the end of evaluation, t = 39 months. Thus, we denote the estimands of interest as V E # (39; γ 0 ) = SCE # (39; γ 0 ). First we illustrate application of all of the methods, and second we evaluate the plausibility of each extra assumption, and, based on this assessment, conduct a substantively relevant sensitivity analysis. We use the yearly scalet = 1 to define the maximum plausible selection bias odds ratio of 1/B or B, with B = 1.5. We construct EUIs and tests for H inf 0 using the approach described in Section 5.2.
The choice of B is important as it strongly affects the width of ignorance intervals and EUIs. Given the authors experience in HIV vaccine efficacy trials, and our lack of involvement in RV144 until after the primary publication, we counted ourselves as suitable experts to specify B. Because the infection rates by τ 0 were very low, per-protocol status is approximately equivalent to adherence status, such that B essentially measures the maximal association, within individuals adherent under the assigned treatment arm, of their infection times with adherence under the opposite treatment arm. Our choice of B = 1.5 reflects our belief that infection time had low association with adherence under the un-assigned arm in subjects already known to be adherent under the assigned arm. Moreover, our choice of relatively small B was influenced by the fact that infection times are the outcome of many constituent factors including demographics, host genetics, sexual behavior, and prevalence/characteristics of HIV in sexual partners, and these factors had limited heterogeneity in this general population study with low representation of extremely high risk groups and with low observed heterogeneity in infection risk (Rerks-Ngarm et al. 2009 ). Given the challenge in selecting B, we recommend reporting results for both the plausible range and nonparametric bounds sensitivity analyses. which V E AP P (39; γ) is significantly > 0. φ AP P = 0.77 corresponds to P P (1) ⊥ P P (0).
When φ AP P = 1, results only vary with β 0 ; thus the OR 1 parameter is irrelevant in the lower-middle contour plot, and the lower-right plot shows V E AP P (39; γ) (γ = β 0 ) with 95% confidence intervals as a function of exp(β 0 ). Next, we evaluate the plausibility of the identifiability assumptions. The consistency part of SUTVA holds because the trial is randomized and only one vaccine regimen was administered in a uniform manner, and the no interference part of SUTVA is plausible because the study sites were geographically dispersed across Thailand, the annual HIV incidence was low (0.2%), and only 1-2 clusters of infected subjects were identified. Ignorable treatment assignment is plausible because there were no recorded problems with the validity of the randomization. Random censoring is difficult to evaluate, but the impact of any violation of this assumption is minimized by the high rates of participant retention (10% drop-out by the terminal visit). SM is plausible, given that fewer subjects were observed to be infected by τ 0 in the vaccine than placebo group (5 versus 10), with S 1 (τ 0 ) = 0.9994 and S 0 (τ 0 ) = 0.9988. AM is plausible but EA is not, given that, among those with an HIV negative test result at the Week 24 visit, the adherence rate was higher in the placebo than vaccine group: 5565 of 7317 (76.1%) versus 5285 of 7234 (73.1%) adherent (Chi-squared test p < 0.0001).
Assumption set C is therefore the strongest plausible assumption set, and we will interpret the results based on this set. From Figure 1 , the estimated ignorance interval (95% EUI) for per-protocol causal vaccine efficacy is 18% to 23% (-30% to 51%) for each of the AP P and ASA1 estimands, such that there is little evidence for positive vaccine efficacy after accounting for potential selection bias. In contrast, the estimated ignorance interval (95% EUI) for V E P P 1 (39; γ 0 ) is 34% to 39% (4% to 95%), indicating evidence for significant positive vaccine efficacy among those who were (or would have been) per-protocol when randomized to vaccine.
The hypothesis tests based on EUIs yield 2-sided p-values of 0.52 for the AP P and ASA1 estimands and 0.03 for the P P 1 estimand.
To assess per-protocol vaccine efficacy over time, we repeated the above analyses for a grid of fixed times t shortly after τ 0 through to τ (9 to 39 months). Supplementary   Figures 1-12 show the estimated ignorance intervals and 95% EUIs for V E # (t; γ 0 ) and for the constituent survival curves S # z (t; γ 0 ), under each assumption set. Under sets B-D, the estimates of V E # (t) decline over time for each estimand, with borderline significant V E # (t) > 0 through about 12-15 months for the plausible range analysis.
In conclusion, the causal sensitivity analysis provides a more interpretable assessment of per-protocol vaccine efficacy than the non-causal result originally reported in Rerks-Ngarm et al. (2009) . Moreover, it provides a more complete account of uncertainty than the original analysis, by accounting for partial non-identifiability as well as for sampling variability. The original estimate of non-causal per-protocol vaccine efficacy was V E = 25%, 95% CI -16% to 51%, p = 0.19, compared to the causal estimates of V E = 18% to 23% (for the AP P and ASA1 estimands), with 95% EUI -30% to 51%, p = 0.52. Thus, the causal analysis provides less evidence for beneficial vaccine efficacy through 39 months in subjects adherent to the full set of immunizations, in both the magnitude and precision of the point estimates. However, the time-dependent analysis indicates marginally significant positive per-protocol vaccine efficacy over the first 12-15 months after accounting for plausible levels of potential selection bias.
For the AP P estimand, the estimated ignorance intervals and EUIs are very wide under assumption set A, for both the semiparametric and nonparametric bounds, raising the question as to what are scenarios where the estimates will be sufficiently narrow to make precise conclusions. In general, both bounds will be narrow when the per-protocol probabilities and the event rates are high in both groups, in which case there is little room for selection bias. In the rare event setting such as for RV144, the semiparametric bounds may still be informatively precise if the per-protocol rates and numbers of events are large. To demonstrate this, Supplementary Figure 13 shows the identical analysis presented in Figure 1 for a second HIV vaccine efficacy trial with a very similar study design, Vax004 (Flynn et al. 2005) , which had much higher per-protocol rates (92.6% and 93.0% in the vaccine and placebo groups) and 3-fold more events (368 HIV infections). The semiparametric estimated ignorance intervals and EUIs are much narrower than for RV144, demonstrating the impact of higher per-protocol rates and greater event numbers, respectively. However, the nonparametric bounds under assumption set A are still very wide, illustrating that in rare event settings the nonparametric bounds are typically uninformative.
Discussion
In clinical trials with survival time endpoint, the standard analysis of per-protocol treatment efficacy contrasts estimates of S P P obs 1 (t) and S P P obs 0 (t). Imbalances in predictors of the survival endpoint between the comparator groups {P P = 1, Z = 1}
and {P P = 1, Z = 0} may easily occur, which renders the analysis non-causal and potentially misleading. Therefore, it is of interest to assess alternative per-protocol estimands that measure a causal effect of treatment. However, such estimands are not identifiable from the observable data plus standard assumptions, which makes a sensitivity analysis generally warranted, and motivates this work.
We defined three survival causal effect (SCE) per-protocol vaccine/treatment effi-cacy parameters of interest-SCE AP P (t), SCE ASA1 (t), SCE P P 1 (t)-and procedures for drawing inferences about these estimands under different assumption sets and specified regions for fixed sensitivity parameters. The estimands have different interpretations and hence different utilities. The AP P estimand may be particularly useful for guiding future research and policies for using the vaccine/treatment, given that always compliers (i.e., always per-protocol subjects) are those who can be expected to adhere to the treatment, and the level of efficacy in this subgroup is an important input parameter for models that predict the treatment's effectiveness in various settings where the adherence pattern may differ from that observed in the clinical trial. The ASA1 estimand measures the treatment effect for the always-survivors who would take treatment, regardless of their adherence under control, and may also be a useful input into treatment effectiveness models. Compared to the AP P estimand, the ASA1 estimand has advantage of identifiability under weaker assumptions, and disadvantage that the ASA1 subpopulation has a less straightforward interpretation, equal to the union of the always per-protocol subpopulation and the always-survivors who would adhere to Z = 1 but not to Z = 0. Reporting results for both estimands may be useful for assessing whether and to what extent treatment efficacy is associated with adherence under Z = 0. For blinded trials of non-toxic treatments, the estimands should be approximately equal, and in fact are exactly equal under the Adherence Monotonicity assumption that adherence to Z = 1 implies adherence to Z = 0. The P P 1 estimand is least useful for evaluating treatment efficacy because by construction it favors the Z = 1 arm, such that its main value may be for assessing the amount of efficacy received for the observable subgroup of subjects who are per-protocol under active treatment Z = 1. An appeal of the P P 1 estimand is that Z = 1 subjects in the P P 1 cohort can be directly observed, and hence directly studied and characterized.
For trials with objective to evaluate per-protocol treatment efficacy, it is valuable to routinely report a sensitivity analysis of these causal estimands, at least for the 
